Knee Osteoarthritis Medication Guide

Current clinical practice guidelines from the Osteoarthritis Research Society International (OARSI) and the American College of Rheumatology (ACR) strongly endorse topical nonsteroidal anti-inflammatory drugs (NSAIDs), such as topical diclofenac, as the first-line pharmacologic intervention for knee osteoarthritis. Topical NSAIDs deliver localized analgesia directly to the synovial joint with minor systemic bioavailability (typically 1–10% of equivalent oral doses), drastically reducing the risk of gastrointestinal ulceration, acute renal impairment, and adverse cardiovascular events.

Recent high-quality systematic reviews and meta-analyses show that acetaminophen provides only a negligible effect size for osteoarthritis pain and function compared to placebo. Consequently, major guidelines have downgraded it from primary therapy. However, it remains a conditional option for short-term episodic relief in patients who have clear contraindications to NSAIDs, provided the total daily dose does not exceed 3,000 mg to mitigate hepatotoxicity risks.

Oral NSAIDs (e.g., celecoxib, naproxen, meloxicam) are recommended when topical formulations yield insufficient pain control. Prescribing rules include:
• Gastrointestinal Protection: Use a selective COX-2 inhibitor or co-prescribe a proton pump inhibitor (PPI) in patients with elevated GI bleed risk.
• Cardiovascular & Renal Monitoring: Baseline blood pressure, estimated glomerular filtration rate (eGFR), and cardiovascular history must be screened.
• Duration: Always utilize the lowest therapeutic dose for the shortest duration necessary during acute symptom flare-ups.

No. Glucosamine and chondroitin sulfate—classified as Symptomatic Slow-Acting Drugs in Osteoarthritis (SYSADOA)—cannot reverse, regrow, or reconstruct loss of articular cartilage once established. While over-the-counter dietary formulations show mixed results in major clinical trials, pharmaceutical-grade crystalline glucosamine sulfate has demonstrated mild anti-inflammatory effects and modest symptom reduction over extended periods in patients with early (mild-to-moderate) radiographic disease.

Duloxetine is a centrally acting serotonin-norepinephrine reuptake inhibitor (SNRI) conditionally recommended for chronic musculoskeletal pain. It is particularly effective for patients with refractory knee pain who exhibit signs of nociplastic pain, central sensitization, or multi-site joint pain, as well as individuals with medical contraindications to traditional anti-inflammatory medications.

Intra-articular steroid injections (e.g., triamcinolone acetonide) provide potent, rapid pain relief and decrease inflammatory joint effusion, typically lasting between 2 and 8 weeks. They serve as an acute management tool to facilitate physical therapy participation. However, repetitive injections (more than 3 to 4 times annually) are discouraged due to randomized controlled data showing an association with accelerated cartilage volume loss over time.

Hyaluronic acid (HA) injections mimic natural synovial fluid to enhance lubrication, viscoelasticity, and shock absorption within the knee joint capsule. While societal guideline recommendations vary, clinical consensus supports its utility in mild-to-moderate osteoarthritis (Kellgren-Lawrence grades 2–3) where it can provide prolonged pain relief for up to 6 months, functioning as a viable non-systemic bridge for patients unable to tolerate NSAIDs.

Platelet-rich plasma (PRP) harnesses concentrated autologous bioactive platelets containing growth factors (such as TGF-beta, PDGF, and IGF-1) to downregulate intra-articular catabolic cytokines. Comparative trials and systematic reviews demonstrate that leukocyte-poor PRP offers superior and longer-lasting analgesic outcomes (often 6 to 12 months) compared to hyaluronic acid and corticosteroids in early-to-moderate disease, although results depend heavily on preparation methods.

Routine use of oral opioids (e.g., oxycodone, morphine, codeine) is strongly discouraged by AAOS, ACR, and OARSI guidelines. Clinical studies show negligible long-term functional improvement alongside substantial risks of tolerance, dependency, cognitive impairment, sedation, and heightened fall rates in elderly populations. Weak atypical opioids like tramadol are considered only as a temporary salvage measure when surgical intervention is contraindicated and all other treatments have failed.

Surgical evaluation (such as high tibial osteotomy for unicompartmental disease or total knee arthroplasty) is indicated when:
• Patients experience persistent, intractable pain and functional disability despite 3 to 6 months of optimized multi-modal medical therapy (medications, structured physical therapy, and weight control).
• Radiographs reveal severe structural joint collapse (Kellgren-Lawrence grade 4 with bone-on-bone contact).
• The patient develops debilitating night pain, progressive fixed flexion contracture, or marked mechanical malalignment (varus/valgus deformity).